Literature DB >> 32140474

Radiographic characteristics of neuroendocrine liver metastases do not predict clinical outcomes following liver resection.

Emily A Armstrong1, Eliza W Beal2, Manisha Shah3, Bhavana Konda3, Sherif Abdel-Misih2, Aslam Ejaz2, Mary E Dillhoff2, Timothy M Pawlik2, Jordan M Cloyd2.   

Abstract

BACKGROUND: Previous research has demonstrated that specific radiographic criteria, including the presence of calcifications and the enhancement pattern on computed tomography (CT) imaging, correlates with clinicopathologic features and outcomes of patients with gastroenteropancreatic neuroendocrine tumors (NET). We sought to investigate whether these radiographic characteristics were prognostic among patients with neuroendocrine liver metastases (NELM) undergoing surgical resection.
METHODS: The preoperative contrast-enhanced CT scans of all patients who underwent resection of NELM at a single institution between 2000-2015 were retrospectively reviewed. The presence of calcifications was determined on non-contrast phase imaging. Enhancement on the arterial phase scan was categorized as hyperenhancing, hypoenhancing, or mixed. Relevant clinicopathologic characteristics as well as recurrence-free survival (RFS) and overall survival (OS) were compared between groups.
RESULTS: Among 82 patients who underwent resection of NELM, 57 had available data on calcifications while 51 had data available on arterial enhancement patterns. Among all patients, median age was 58 (IQR: 47-63) and the majority were female (N=48, 59.5%). The most common primary tumor locations were pancreas (N=25, 30.5%) and small bowel (N=27, 32.9%). The most commonly performed operations were right hepatectomy (N=29, 35.4%), bisegmentectomy (N=15, 18.3%), and segmentectomy (N=14, 17.1%). Median tumor number was 4 (IQR: 2-9), median Ki-67 was 5% (IQR: 2-10%), and median size of the largest liver metastasis was 4.5 (IQR: 2.8-7.7) cm. Twelve (21%) patients had tumor calcifications. Among patients with and without calcifications there were no differences in demographics, clinicopathologic characteristics, RFS (P=0.772) or OS (P=0.095). Arterial enhancement was hypoenhancing in 23 (45.1%), hyperenhancing in 10 (19.6%), and mixed in 18 (35.3%). Similarly, there were no differences between arterial enhancement groups in demographics, clinicopathologic characteristics, RFS (P=0.618) or OS (P=0.268).
CONCLUSIONS: Radiographic characteristics on contrast-enhanced CT are not associated with the outcomes of patients undergoing resection of NELM. Future investigations should evaluate the prognostic impact of functional neuroendocrine imaging. 2020 Hepatobiliary Surgery and Nutrition. All rights reserved.

Entities:  

Keywords:  Neuroendocrine tumor (NET); carcinoid; hepatectomy; prognosis; radiomics

Year:  2020        PMID: 32140474      PMCID: PMC7026776          DOI: 10.21037/hbsn.2019.06.02

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  29 in total

Review 1.  Recommendations for management of patients with neuroendocrine liver metastases.

Authors:  Andrea Frilling; Irvin M Modlin; Mark Kidd; Christopher Russell; Stefan Breitenstein; Riad Salem; Dik Kwekkeboom; Wan-yee Lau; Catherine Klersy; Valerie Vilgrain; Brian Davidson; Mark Siegler; Martyn Caplin; Enrico Solcia; Richard Schilsky
Journal:  Lancet Oncol       Date:  2014-01       Impact factor: 41.316

2.  The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.

Authors:  Chien-Ting Liu; Ming-Huang Chen; Jen-Shi Chen; Li-Tzong Chen; Yan-Shen Shan; Chang-Hsien Lu; Yu-Li Su; Fan-Chen Ku; Wen-Chi Chou; Yen-Yang Chen
Journal:  Asia Pac J Clin Oncol       Date:  2016-06-30       Impact factor: 2.601

3.  Effect of pre-enhancement set point on computed tomographic perfusion values in normal liver and metastases to the liver from neuroendocrine tumors.

Authors:  Chaan S Ng; Adam G Chandler; James C Yao; Delise H Herron; Ella F Anderson; Chusilp Charnsangavej; Brian P Hobbs
Journal:  J Comput Assist Tomogr       Date:  2014 Jul-Aug       Impact factor: 1.826

Review 4.  When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations.

Authors:  Mickaël Lesurtel; David M Nagorney; Vincenzo Mazzaferro; Robert T Jensen; Graeme J Poston
Journal:  HPB (Oxford)       Date:  2014-03-17       Impact factor: 3.647

5.  Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis.

Authors:  F M Watzka; C Fottner; M Miederer; A Schad; M M Weber; G Otto; H Lang; T J Musholt
Journal:  Langenbecks Arch Surg       Date:  2015-02-15       Impact factor: 3.445

6.  CT differentiation of poorly-differentiated gastric neuroendocrine tumours from well-differentiated neuroendocrine tumours and gastric adenocarcinomas.

Authors:  Seong Ho Kim; Se Hyung Kim; Min-A Kim; Cheong-il Shin; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

7.  Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making.

Authors:  Emilio Bertani; Massimo Falconi; Chiara Grana; Edoardo Botteri; Antonio Chiappa; Pasquale Misitano; Francesca Spada; Davide Ravizza; Barbara Bazolli; Nicola Fazio
Journal:  Int J Surg       Date:  2015-06-11       Impact factor: 6.071

Review 8.  Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies.

Authors:  Skye C Mayo; Joseph M Herman; David Cosgrove; Nik Bhagat; Ihab Kamel; Jean-Francois H Geschwind; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2012-10-11       Impact factor: 6.113

9.  Pancreatic neuroendocrine tumour (PNET): Staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma.

Authors:  Jung Hoon Kim; Hyo Won Eun; Young Jae Kim; Jeong Min Lee; Joon Koo Han; Byung-Ihn Choi
Journal:  Eur Radiol       Date:  2015-08-08       Impact factor: 5.315

10.  Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?

Authors:  Laura Catena; Ettore Bichisao; Massimo Milione; Monica Valente; Marco Platania; Sara Pusceddu; Monika Ducceschi; Nicoletta Zilembo; Barbara Formisano; Emilio Bajetta
Journal:  Tumori       Date:  2011 Sep-Oct
View more
  4 in total

1.  Radiographic features and behaviors of neuroendocrine tumors: can we judge a book by its cover?

Authors:  Tyler J Mouw; Charles R Scoggins
Journal:  Hepatobiliary Surg Nutr       Date:  2021-08       Impact factor: 7.293

Review 2.  Neuroendocrine liver metastases: a contemporary review of treatment strategies.

Authors:  Jordan M Cloyd; Aslam Ejaz; Bhavana Konda; Mina S Makary; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2020-08       Impact factor: 7.293

3.  Highly variable biodistribution of 68Ga labeled somatostatin analogues 68Ga-DOTA-NOC and 68Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT.

Authors:  Monica Cheng; Mark Tann
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

4.  Management of neuroendocrine liver metastasis: Searching for new prognostic factor and appraising repeat hepatectomy.

Authors:  Junichi Arita; Sho Kiritani; Kiyoshi Hasegawa
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.